



# HHS Public Access

Author manuscript

*Biochemistry*. Author manuscript; available in PMC 2017 August 23.

Published in final edited form as:

*Biochemistry*. 2016 August 23; 55(33): 4731–4736. doi:10.1021/acs.biochem.6b00658.

## SAICAR activates PKM2 in its dimeric form

Ming Yan<sup>†,‡</sup>, Srinivas Chakravarthy<sup>§</sup>, Joshua M. Tokuda<sup>¶</sup>, Lois Pollack<sup>¶</sup>, Gregory D. Bowman<sup>†,\*</sup>, and Young-Sam Lee<sup>‡,\*</sup>

<sup>†</sup>T.C. Jenkins Department of Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, USA

<sup>‡</sup>Department of Biology, Johns Hopkins University, Baltimore, Maryland 21218, USA

<sup>§</sup>Biophysics Collaborative Access Team, Argonne National Laboratory, Argonne, Illinois 60439, USA.

<sup>¶</sup>School of Applied and Engineering Physics, Cornell University, Ithaca, New York 14853, USA

### Abstract

Human pyruvate kinase isoform M2 (PKM2) is a glycolytic enzyme isoform implicated in cancer. Malignant cancer cells have higher levels of dimeric PKM2, which is regarded as an inactive form of tetrameric pyruvate kinase. This perceived inactivity has fueled controversy over how the dimeric form of pyruvate kinase might contribute to cancer. Here we investigate enzymatic properties of PKM2<sup>G415R</sup>, a variant derived from a cancer patient, which we show by size-exclusion chromatography and SAXS to be a dimer that cannot form tetramer in solution. Although PKM2<sup>G415R</sup> binds to FBP, unlike wildtype this PKM2 variant shows no activation by FBP. In contrast, PKM2<sup>G415R</sup> is activated by the SAICAR, an endogenous metabolite that we previously showed correlates with increased cell proliferation and promotes protein kinase activity of PKM2. Our results demonstrate an important and unexpected enzymatic activity of the PKM2 dimer that likely has a key role in cancer progression.

### Keywords

Pyruvate kinase; Quaternary structure; SAICAR

---

\*Corresponding Authors Gregory D. Bowman, T.C. Jenkins Department of Biophysics, Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, USA; Phone: (410) 516-7850; gdbowman@jhu.edu; Young-Sam Lee, Department of Biology, Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, USA; Phone: (410) 516-4147; ylee99@jhu.edu.

**Supporting Information.** Figure S1 showing additional SAXS results. This material is available free of charge via the Internet at <http://pubs.acs.org>.

#### Author Contributions

M. Y. prepared all reagents and performed biochemical experiments; S. C., J.M.T., and L. P. carried out SAXS experiments and analysis; M.Y., Y.-S.L., and G.D.B. designed experiments and analyzed data; Y.-S.L. and G.D.B. conceived the project; M.Y., Y.-S.L., and G.D.B. wrote the manuscript.

## INTRODUCTION

Pyruvate kinase isoform M2 (PKM2) is one of four human pyruvate kinase isoforms (1, 2) that, unlike other pyruvate kinases, is enriched in many types of cancer (2). Highlighting its importance in cell proliferation, replacement of PKM2 with other pyruvate kinase isoforms hinders cancer cell survival and growth (3). Interestingly, PKM2 has long been used as a marker for cancer. In cancerous cells, PKM2 is abundantly found as a dimer, with the level of PKM2 dimer correlated with malignancy and thus has been named tumor PKM2 (4). How PKM2 contributes to malignancy is still controversial, but is believed to arise from a combination of metabolic (5) and cell signaling roles (6).

Although found to exist in different oligomeric forms in cells, like other pyruvate kinases, PKM2 is considered to have maximal pyruvate kinase activity as a tetramer (7). Earlier biochemical studies found the PKM2 dimer to be a nearly inactive (7). The low activity of the dimer was because of a  $K_M$  for phosphoenolpyruvate (PEP) that is much higher than physiological PEP concentrations, while the tetrameric PKM2 has a low  $\mu\text{M}$   $K_M$  for PEP (7). This led to the belief that the dimeric PKM2 is a nearly inactive enzyme at physiological PEP concentrations. How a nearly inactive form of pyruvate kinase might contribute to cell proliferation has been unclear. Initially it was thought that the nearly inactive pyruvate kinase allows cancer cells to divert more glycolytic intermediates to anabolic processes (5). However, recent evidence shows that the dimeric PKM2 may have an additional active role in cell growth (8-14).

In addition to its classical role in generating ATP from ADP and the phosphate donor PEP, PKM2 also has been found to phosphorylate protein substrates (9, 10, 12-16). A significant fraction of PKM2 in cancer cells is located in the nucleus (17) and this proportion increases when cancer cell proliferation is stimulated (14). Purification of this nuclear PKM2 showed that it can phosphorylate various nuclear proteins using PEP as a phosphate source (9-11, 16). Mutational studies such as ones using the variant PKM2<sup>R399E</sup> showed that this dimer-prone mutant promotes PKM2's unusual protein kinase activity (13-15). This led to the belief that dimeric PKM2 may be responsible for the unusual signaling activity and contribute to cancer. However, a challenging aspect of this model is how dimeric PKM2 could maintain significant activity given its high  $K_M$  for PEP that, under physiological conditions, would severely limit the ability to phosphorylate protein substrates.

Both the oligomeric state and activity of PKM2 are influenced by bound ligands. For decades, PKM2 and several other pyruvate kinase isoforms like PKL and PKR have been known to be induced by fructose-1, 6-bisphosphate (FBP) (18, 19). The binding of FBP shifts PKM2 to a tetrameric oligomeric state and lowers the  $K_M$  for PEP (7). More recently, we reported that SAICAR, an intermediate of *de novo* purine nucleotide biosynthesis, activates PKM2 in an isozyme-specific manner (12). SAICAR levels are enriched when cancer cells are in stress conditions, and binding of SAICAR to PKM2 promotes cancer cell survival (12). In addition, the binding of SAICAR induces the protein kinase activity of PKM2 *in vitro* and in cultured cancer cells (16).

Given the apparent switch in substrate specificity upon binding to SAICAR and the prevalence of dimeric PKM2 in cancer, we sought to determine whether there was a connection between SAICAR binding and the oligomeric state of PKM2. Here we report that SAICAR stimulates PKM2 dimer without inducing formation of a PKM2 tetramer. We focused on a PKM2 variant identified in patient-derived tumors, PKM2<sup>G415R</sup> (20), and show that this variant can bind to FBP but does not form tetramer. FBP cannot activate PKM2<sup>G415R</sup>, suggesting that FBP-mediated PKM2 activation requires the tetramerization of PKM2. SAICAR, on the other hand, still activates PKM2<sup>G415R</sup>, and in fact binds better to the dimeric form of PKM2 and improves substrate binding. Our results support an active role for the PKM2 dimer in cancer, and suggest that the allosteric activation of PKM2 by SAICAR may in fact preferentially act via the dimeric form.

## EXPERIMENTAL PROCEDURES

### Materials

Plasmid encoding GST-PKM2 in pGEX-6P-1 vector (GE Life Sciences) was custom synthesized by GenScript. Oligonucleotides were synthesized by Operon. Site directed mutagenesis was done using QuikChange XL II kits (Stratagene) and confirmed by sequencing from the T7 promoter and from the T7 terminator sites. Lactate dehydrogenase (LDH) was purchased from Roche. SAICAR was purchased from Toronto Research Chemicals. All other chemicals were from Sigma-Aldrich unless specifically noted otherwise.

### Protein Expression and Purification

PKM2 wild type and mutants were expressed and purified from *Escherichia coli* strain Rosetta (DE3) pLysS (Novagen). Cells were grown in Terrific Broth at 37°C, and the protein expression was induced by the addition of isopropyl-β-D-thiogalactopyranoside (IPTG, 0.5 mM) followed by an incubation for 18 hours at 16°C. Following steps were carried out at 4°C or on ice unless noted otherwise. Cells were collected by centrifugation (4,000 g for 20 min), and the pellet was resuspended in buffer A (20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 1 mM EDTA, 1 mM DTT). Cells were lysed by sonication, and debris was removed by centrifugation (45,000 g for 45 min) and then filtration through a 1.1 micron glass fiber filter (Thermo Scientific). The supernatant was loaded onto a 5 ml GStrap column (GE Life Sciences) pre-equilibrated in buffer A. The resin was washed with buffer A, and the bound protein was eluted with a linear gradient of buffer B (20 mM Tris-HCl, pH 8, 500 mM NaCl, 1 mM EDTA, 1 mM DTT, 10 mM reduced glutathione) over 20 column volumes. Fractions containing target protein were combined and digested with PreScission protease ((21), GE Life Sciences) in buffer C (50 mM Tris-HCl, pH 6.9, 150 mM NaCl, 1 mM EDTA, 1 mM DTT) overnight. Cleaved proteins were purified by gel filtration chromatography on a HiLoad 16/600 Superdex 200 column (GE Healthcare) with buffer D (10 mM HEPES pH7, 150 mM NaCl, 5 mM MgCl<sub>2</sub>, 0.25 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP)). The protein concentrations were determined by measuring the absorbance at 280 nm in denaturing conditions, using a calculated extinction coefficient of 29,910 M<sup>-1</sup> cm<sup>-1</sup> (22, 23). Protein contents were analyzed by SDS-PAGE and Coomassie Blue staining.

### Pyruvate Kinase Activity Assay

Enzyme activity was measured in vitro with a lactate dehydrogenase (LDH) coupled assay as previously described (12). PKM2 were diluted to the desired concentration in the assay buffer (50 mM Tris-HCl, pH 7.6, 100 mM KCl, 6.2 mM MgCl<sub>2</sub>, 1 mM DTT) and incubated with ligands at 37°C for 30 minutes in a UV-transparent 96-well plate. After incubation, ADP (final concentration 2 mM), NADH (final concentration 220 μM), and LDH (final concentration 5 units/ml) were added to the solution. Reactions were initiated by the addition of PEP (final concentration 150 μM for typical experiments). The rate of NADH oxidation was spectroscopically measured at 340 nm using a Tecan Infinite M2 microplate reader.

### Size-exclusion Chromatography

Size exclusion chromatography was carried out using Superdex S200 10/300 GL column (GE Healthcare). Purified PKM2<sup>WT</sup> or PKM2<sup>G415R</sup> (0.20 mL in buffer D) was loaded onto the column and eluted with buffer D (0.3 mL/min at 4°C). Samples with FBP or SAICAR were incubated for one hour at 4°C or at 18°C before loading.

### Small Angle X-Ray Scattering

Size exclusion chromatography small angle X-ray scattering (SEC-SAXS) experiments were performed at BioCAT (beamline 18-ID, Advanced Photon Source at Argonne National Laboratory (24)). The instrument used for the experiment used a 12 KeV (1.03 Å) X-ray beam and a Pilatus 3 1M detector (Dectris). Samples were passed through a Superdex 200 Increase 10/300 GL column (GE Life Sciences), and the eluted solution was directed to a 1.5 mm quartz capillary sample cell at a rate of 0.75 mL/min. The sample-to-detector distance was ~ 3.5 m, which resulted in a q-range of 0.004-0.38 Å<sup>-1</sup> (0.5 sec exposure every 2 sec). Data were corrected for background scattering by subtracting the buffer signal. Radius of gyration ( $R_g$ ) values were calculated from Guinier approximations and P(R) curves using PRIMUS (25).

### Isothermal Titration Calorimetry (ITC)

ITC measurements were performed by using a Microcal ITC<sub>200</sub> calorimeter at 25.0°C. Protein solutions were dialyzed against buffer D. Ligands were dissolved in buffer D. Both protein and ligand solutions were degassed in vacuum before use. PKM2<sup>WT</sup> or PKM2<sup>G415R</sup> solution (300 μM, 0.22 mL) was placed in the sample cell. FBP or SAICAR solution (3 mM, 20 injections of 2 μL /injection) was injected with 180 s intervals. The baseline-corrected data were analyzed with Microcal Origin software.

## RESULTS

### PKM2<sup>G415R</sup> mutant does not form tetramer in solution

To isolate the potential activities for a dimeric form of PKM2, we sought to find a PKM2 variant unable to form a tetramer. Given that PKM2 has long been known to preferentially form a dimer in cancers, known as a “tumor dimer”, we analyzed the locations of mutations in PKM2 isolated from patient-derived tumors (20). One amino acid change, a glycine-to-

arginine mutation at position 415 (G415R), is located at the dimer-dimer interface of the PKM2 tetramer (Figure 1A). Based on its location at the interface and the introduction of two opposing positive charges, we speculated that this change might disrupt tetramer formation.

To test this hypothesis, human PKM2<sup>G415R</sup> was recombinantly expressed and purified from *E. coli* and compared to human PKM2<sup>WT</sup> by gel filtration chromatography (Figure 1B and 1C). At low  $\mu\text{M}$  protein concentrations, PKM2<sup>WT</sup> eluted at two major peak positions, which we interpret as tetrameric and dimeric species. We observed that either increasing concentrations of PKM2<sup>WT</sup> or addition of FBP predominantly shifted the elution profile to the larger species, consistent with the larger species corresponding to a tetramer and smaller species a dimer. In contrast to wildtype, PKM2<sup>G415R</sup> eluted in a single peak corresponding to the smaller dimeric species, and failed to shift to the larger tetrameric profile at high (100  $\mu\text{M}$ ) protein concentration or with the addition of FBP.

To independently verify that these gel filtration elution profiles reflect differences in oligomeric states, radius of gyration ( $R_g$ ) values of wild-type and variant PKM2 were determined using SAXS (26) (Figure 1D). To minimize aggregation, SAXS measurements were recorded following an inline size-exclusion column. To maximize signal-to-noise, PKM2 variants were applied to the column at 100  $\mu\text{M}$  concentrations. PKM2<sup>WT</sup> had an  $R_g$  value of 43 Å (Figure 1D and Supplementary Figure S1), consistent with the  $R_g$  value calculated from crystallographic structures of tetrameric PKM2 (41 Å). The binding of FBP did not significantly alter the  $R_g$  of PKM2<sup>WT</sup> (41 Å), which is expected at the high concentrations used in these experiments. On the other hand, PKM2<sup>G415R</sup> showed a much smaller  $R_g$  value (33 Å; Figure 1D and Supplementary Figure S1). Guinier plots of these SAXS data showed that the molecular weight of PKM2<sup>G415R</sup> in solution is approximately one half of the PKM2<sup>WT</sup> tetramer in solution (Figure S1). The  $R_g$  was not affected by FBP and was nearly identical to the  $R_g$  value expected from a half of tetrameric PKM2 (34 Å). These SAXS results showed that PKM2<sup>G415R</sup> indeed remains as a dimer even at high protein concentration or in the presence of FBP.

### **The PKM2<sup>G415R</sup> dimer is in its tense form and cannot be activated by FBP**

To assess the activation and properties of the PKM2 dimer, we measured the pyruvate kinase activity of PKM2<sup>G415R</sup> with varying ADP and PEP concentrations (Figure 2). Previous work found the dimeric form of PKM2<sup>WT</sup> to have relatively low activity, and be considered to be in a tense form (7). Here, we found PKM2<sup>G415R</sup> to have a weak affinity to PEP ( $K_M$  1.2 mM PEP;  $k_{\text{cat}}$  0.57  $\text{s}^{-1}$ ) and a low millimolar  $K_M$  for ADP (0.25 mM ADP). These values are comparable to the tense form reported for wildtype PKM2 dimer (7, 12).

FBP is well-known for promoting the tetramerization and coincident activation of PKM2 (6, 27). Our SAXS and size-exclusion experiments showed that FBP is unable to convert PKM2<sup>G415R</sup> to a tetrameric form (Fig 1). To see the extent that activity might be impacted, we compared pyruvate kinase activities of PKM2<sup>WT</sup> and PKM2<sup>G415R</sup> at varying FBP concentrations (Figure 3A). In contrast to the clear activation of PKM2<sup>WT</sup>, PKM2<sup>G415R</sup> appeared to be unaffected by the presence of FBP and remain in the tense form.

A simple possibility to explain these results could be that the G415R substitution interferes with FBP binding. To determine whether FBP still binds to PKM2<sup>G415R</sup>, the interaction of FBP with PKM2 was analyzed by isothermal titration calorimetry (ITC; Figure 3B-C). For PKM2<sup>WT</sup>, we observed an apparent binding isotherm consistent with a sub- $\mu\text{M}$   $K_D$  (Figure 3B). The enthalpy contribution to the binding suggests that FBP induced formation of the PKM2 tetramer (calculated buried surface area 2400  $\text{\AA}^2$ ). Interestingly, for PKM2<sup>G415R</sup>, titration of FBP promoted a clear change in measured heat released, with a  $K_D$  approximately 5-fold higher than that of PKM2<sup>WT</sup> (Figure 3C). Compared to the FBP-PKM2<sup>WT</sup> interaction, the enthalpy contribution was much smaller and consistent of FBP binding (buried surface area 326  $\text{\AA}^2$ ) without drastic changes in PKM2 quaternary structure. Taken together, these results demonstrate that PKM2<sup>G415R</sup> can bind to FBP, but fails to exhibit activation in concert with conversion to a tetrameric form.

### The PKM2<sup>G415R</sup> dimer can be activated by SAICAR without forming tetramer

Our previous work showed that PKM2<sup>WT</sup> can be activated by SAICAR (12). To see if activation might be intrinsically coupled to formation of the PKM2 tetramer, we monitored the distribution of size exclusion peaks after incubation with SAICAR. The addition of SAICAR had no measurable effects on oligomeric state for either PKM2<sup>WT</sup> or PKM2<sup>G415R</sup> (Fig 1). This raised the possibility that SAICAR primarily exerts its influence on PKM2 without altering its oligomerization state. Given the inability of PKM2<sup>G415R</sup> to tetramerize, we therefore used this cancer variant to investigate whether SAICAR could stimulate the dimeric form of PKM2. Remarkably, pyruvate kinase assays performed showed a distinct 2-fold activation by SAICAR ( $EC_{50}$   $60 \pm 20 \mu\text{M}$ ;  $1.0 \pm 0.4$  SAICAR per PKM2 monomer; Figure 4A). Importantly, the  $EC_{50}$  is approximately 5-fold lower than the  $EC_{50}$  (0.3 mM) observed with PKM2<sup>WT</sup> activation by SAICAR (12), suggesting that SAICAR binds to PKM2<sup>G415R</sup> better than to PKM2<sup>WT</sup>.

Tighter binding of SAICAR to PKM2<sup>G415R</sup> compared with PKM2<sup>WT</sup> was further supported by ITC experiments (Figure 4B-C). Compared with PKM2<sup>WT</sup>, which bound to SAICAR with an affinity of  $300 \pm 90 \mu\text{M}$ , PKM2<sup>G415R</sup> bound to SAICAR significantly better, with a  $K_D$  of  $12 \pm 3 \mu\text{M}$ . Taken together, these results demonstrate that SAICAR binds to PKM2 dimer and activates it without inducing tetramer.

Taken together, these results show that there are two different modes of activating inactive dimeric PKM2 (Figure 5). First, dimeric PKM2 can be activated by becoming tetrameric PKM2. This oligomerization state change is induced by FBP. Alternatively, inactive PKM2 dimer can be activated by forming an active PKM2 dimer. SAICAR binding is an example where inactive PKM2 dimer becomes an active one without having its oligomerization state altered. The PKM2<sup>G415R</sup> variant from patient-derived tumor shows that the tetramer formation is dispensable and that it can be activated by an alternative mechanism.

## DISCUSSION AND CONCLUSIONS

The relevance of PKM2 in cancer has been demonstrated in multiple systems (6, 27, 28). Interestingly, highly proliferating cells have higher levels of dimeric PKM2, which was widely considered to be an inactive form of pyruvate kinase. Many different models have



been proposed to explain how nearly inactive pyruvate kinase can contribute to malignant cell growth. The results presented here show that dimeric PKM2 should not be considered a constitutively inactive form, but one that can be specifically activated by ligands such as SAICAR.

Our findings open new possibilities for regulation and activation of PKM2. Whereas tetramerization is one route to PKM2 activation, the PKM2 dimer is not merely an inactive pool but represents a physiologically important target for specific activation. Our findings that SAICAR bound more tightly to the dimeric PKM2<sup>G415R</sup> variant suggests that the dimeric form can be targeted by unique regulatory ligands that allow for richer responses to the metabolic state of the cell. We speculate that the pressure for high proliferative growth in cancer cells selects for variants of PKM2 such as G415R that stabilize the dimeric state, which in turn favor ligand binding and biochemical properties of the PKM2 dimer. With dual substrate specificity, the ability of PKM2 to phosphorylate protein targets has been linked to cellular proliferation (6, 10, 13, 16, 28). We previously reported that SAICAR-bound PKM2 can phosphorylate proteins much more efficiently than the FBP-bound form (16). The higher activity we report here for dimeric PKM2 in the presence of SAICAR is consistent with the previous suggestion that protein kinase activity is accomplished by the dimeric form (6). We anticipate that other means of controlling the dimertetramer equilibrium, such as through post-translational modifications, will also be uncovered, and that proper allosteric regulation of the PKM2 dimer will prove to be an important contributor to cellular adaptation.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGMENT

We thank Shelby Winans for the preparation of the PKM2<sup>G415R</sup> plasmid, and Cynthia Wolberger and Beverly Wendland for allowing us to use their equipment.

### Funding Sources

This work was supported by National Institute of Health grants (R21CA181751 to G.D.B. and Y.-S.L.; R01CA168658 to Y.-S.L.). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DEAC02-06CH11357. SAXS experiment was supported by grant 9 P41 GM103622 from the National Institute of General Medical Sciences of the National Institutes of Health. Use of the Pilatus 3 1M detector was provided by grant 1S10OD018090-01 from NIGMS.

## ABBREVIATIONS

<b>PKM2</b>	pyruvate kinase isoform M2
<b>FBP</b>	fructose-1,6-bisphosphate
<b>SAICAR</b>	succinyl-5-aminoimidazole-4-carboxamide-1-ribose-5'-phosphate
<b>ITC</b>	isothermal titration calorimetry
<b>SAXS</b>	small angle X-ray scattering


## REFERENCES

- (1). Filipp FV. Cancer metabolism meets systems biology: Pyruvate kinase isoform PKM2 is a metabolic master regulator. *J. Carcinog.* 2013; 12:14. [PubMed: 23961261]
- (2). Macintyre AN, Rathmell JC. PKM2 and the Tricky Balance of Growth and Energy in Cancer. *Mol. Cell.* 2011; 42:713–714. [PubMed: 21700216]
- (3). Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature.* 2008; 452:230–233. [PubMed: 18337823]
- (4). Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. *Semin. Cancer Biol.* 2005; 15:300–308. [PubMed: 15908230]
- (5). Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science.* 2009; 324:1029–1033. [PubMed: 19460998]
- (6). Yang W, Lu Z. Pyruvate kinase M2 at a glance. *J. Cell Sci.* 2015; 128:1655–1660. [PubMed: 25770102]
- (7). Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. *Biochemistry.* 2005; 44:9417–9429. [PubMed: 15996096]
- (8). Gao X, Wang H, Yang JJ, Chen J, Jie J, Li L, Zhang Y, Liu ZR. Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals. *J. Biol. Chem.* 2013; 288:15971–15979. [PubMed: 23576436]
- (9). Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, Lyssiotis CA, Aldape K, Cantley LC, Lu Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. *Nat. Cell Biol.* 2012; 14:1295–1304. [PubMed: 23178880]
- (10). Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK, Lu Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. *Cell.* 2012; 150:685–696. [PubMed: 22901803]
- (11). Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, You MJ, Koh MY, Cote G, Aldape K, Li Y, Verma IM, Chiao PJ, Lu Z. EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis. *Mol. Cell.* 2012; 48:771–784. [PubMed: 23123196]
- (12). Keller KE, Tan IS, Lee YS. SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. *Science.* 2012; 338:1069–1072. [PubMed: 23086999]
- (13). Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. *Mol. Cell.* 2012; 45:598–609. [PubMed: 22306293]
- (14). Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K, Lu Z. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. *Nature.* 2011; 480:118–122. [PubMed: 22056988]
- (15). Yang W, Lu Z. Nuclear PKM2 regulates the Warburg effect. *Cell Cycle.* 2013; 12:3154–3158. [PubMed: 24013426]
- (16). Keller KE, Doctor ZM, Dwyer ZW, Lee YS. SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. *Mol. Cell.* 2014; 53:700–709. [PubMed: 24606918]
- (17). Stetak A, Veress R, Ovadi J, Csermely P, Keri G, Ullrich A. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. *Cancer Res.* 2007; 67:1602–1608. [PubMed: 17308100]
- (18). Taylor CB, Bailey E. Activation of liver pyruvate kinase by fructose 1,6-diphosphate. *Biochem. J.* 1967; 102:32C–33C.
- (19). Kahn A, Marie J, Boivin P. Pyruvate kinase isozymes in man. II. L type and erythrocyte-type isozymes. *Electrofocusing and immunologic studies. Hum. Genet.* 1976; 33:35–46. [PubMed: 820628]
- (20). Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG. PKM2 isoform-specific deletion




reveals a differential requirement for pyruvate kinase in tumor cells. *Cell*. 2013; 155:397–409. [PubMed: 24120138]


- (21). Walker PA, Leong LEC, Ng PWP, Tan SH, Waller S, Murphy D, Porter AG. Efficient and Rapid Affinity Purification of Proteins Using Recombinant Fusion Proteases. *Biotechnology*. 1994; 12:601–605. [PubMed: 7764949]
- (22). Edelhoch H. Spectroscopic determination of tryptophan and tyrosine in proteins. *Biochemistry*. 1967; 6:1948–1954. [PubMed: 6049437]
- (23). Gasteiger, E.; Hoogland, C.; Gattiker, A.; Duvaud, S.; Wilkins, MR.; Appel, RD.; Bairoch, A. *Proteomics Protocols Handbook*. Humana Press; Totowa: 2005. p. 571-607.
- (24). Mathew E, Mirza A, Menhart N. Liquid-chromatography-coupled SAXS for accurate sizing of aggregating proteins. *J. Synchrotron. Radiat.* 2004; 11:314–318. [PubMed: 15211037]
- (25). Konarev PV, Volkov VV, Sokolova AV, Koch MHJ, Svergun DI. PRIMUS: a Windows PC-based system for small-angle scattering data analysis. *J. Appl. Crystallogr.* 2003; 36:1277–1282.
- (26). Kikhney AG, Svergun DI. A practical guide to small angle X-ray scattering (SAXS) of flexible and intrinsically disordered proteins. *FEBS Lett.* 2015; 589:2570–2577. [PubMed: 26320411]
- (27). Israelsen WJ, Vander Heiden MG. Pyruvate kinase: Function, regulation and role in cancer. *Semin. Cell Dev. Biol.* 2015; 43:43–51. [PubMed: 26277545]
- (28). Dong G, Mao Q, Xia W, Xu Y, Wang J, Xu L, Jiang F. PKM2 and cancer: The function of PKM2 beyond glycolysis. *Oncol. Lett.* 2016; 11:1980–1986. [PubMed: 26998110]
- (29). Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD, Malstrom S, Khan TM, Kung C, Skoumbourdis AP, Veith H, Southall N, Walsh MJ, Brimacombe KR, Leister W, Lunt SY, Johnson ZR, Yen KE, Kunii K, Davidson SM, Christofk HR, Austin CP, Inglese J, Harris MH, Asara JM, Stephanopoulos G, Salituro FG, Jin S, Dang L, Auld DS, Park HW, Cantley LC, Thomas CJ, Vander Heiden MG. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. *Nat. Chem. Biol.* 2012; 8:839–847. [PubMed: 22922757]




**Figure 1.** PKM2<sup>G415R</sup> is constitutively a dimer. **(A)** Structure of the PKM2 tetramer (PDB code 3ME3; (29)). The Ca of residue G415 is shown as a black sphere in each of the four chains. **(B)** PKM2<sup>WT</sup> (top) but not PKM2<sup>G415R</sup> (bottom) displays a concentration dependent gel-filtration elution changes. **(C)** FBP does not alter the oligomeric state of PKM2<sup>G415R</sup>. Gel filtration experiments show PKM2<sup>WT</sup> to have an FBP-dependent shift, whereas PKM2<sup>G415R</sup> was unaffected. **(D)** Small-angle X-ray scattering experiments suggest that PKM2<sup>G415R</sup> is constitutively a dimer. Values for the radius of gyration ( $R_g$ ) of PKM2<sup>WT</sup> and PKM2<sup>G415R</sup> were calculated from Guiner plots, using scattering data taken with PKM2 in the presence and absence of FBP. For reference, the  $R_g$  values calculated from a PKM2 tetramer crystallographic structure (PDB code 3ME3, chains A-D) or a hypothetical dimer (chains A and B only) are shown as dashed lines.




**Figure 2.** Pyruvate kinase activity of PKM2<sup>G415R</sup>. (A) With titration of PEP, the PKM2<sup>G415R</sup> variant shows a  $K_M$  of 1.2 mM PEP and  $k_{cat}$  0.57 sec<sup>-1</sup>. (B) With titration of ADP, PKM2<sup>G415R</sup> shows a  $K_M$  of 0.25 mM ADP.



**Figure 3.** PKM2<sup>G415R</sup> binds to FBP but is not activated. **(A)** Pyruvate kinase activity of PKM2<sup>WT</sup> (filled circles) and PKM2<sup>G415R</sup> (empty circles) in the presence of FBP. **(B and C)** Isothermal titration calorimetric analysis of FBP binding to **(B)** PKM2<sup>WT</sup> (0.54 sites,  $K_d$  0.21  $\mu\text{M}$ ,  $H$ : -12.2 kcal/mole) and **(C)** PKM2<sup>G415R</sup> (1.0 sites,  $K_d$  1.0  $\mu\text{M}$ ,  $H$  -4.7 kcal/mole).



**Figure 4.** SAICAR still binds to PKM2<sup>G415R</sup> and activates it. **(A)** Normalized pyruvate kinase activity of PKM2<sup>G415R</sup> in the presence of SAICAR. **(B and C)** Isothermal titration calorimetric analysis of SAICAR binding to **(B)** PKM2<sup>WT</sup> (1.0 site per PKM2<sup>WT</sup> monomer;  $K_d$  300  $\mu$ M;  $\Delta H$  -5 kcal/mole) and **(C)** PKM2<sup>G415R</sup> (0.48 site per PKM2<sup>G415R</sup> monomer;  $K_d$  12  $\mu$ M,  $\Delta H$  -1.4 kcal/mole).



**Figure 5.**  
Different modes of PKM2 activation by FBP and SAICAR.